文献速递血栓与止血

ITP患者从艾曲泊帕或罗米司亭换用阿伐曲泊帕的真实世界治疗模式与结局:REAL-AVA 3.5研究

Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study.
PubMed 文献 · Br J Haematol · 2026-05-14

本研究为回顾性病历审查,纳入201例在停用艾曲泊帕或罗米司亭后30天内换用阿伐曲泊帕且随访≥6个月的成人原发免疫性血小板减少症患者。最常见换药原因为疗效不足(59.2%)。基线血小板<30×10^9/L者中,98.7%和94.9%分别达到≥30×10^9/L和≥50×10^9/L;中位缓解持久性分别为93.8%、89.6%和67.4%。多数换药患者获得或维持了临床有意义且持久的血小板应答。

要点

  • 换用阿伐曲泊帕最常见原因为前药疗效不足(59.2%)。
  • 基线血小板<30×10^9/L者中98.7%达到≥30×10^9/L。
  • ≥30×10^9/L应答的中位持久性达93.8%。

核心结论

  • 多数从艾曲泊帕或罗米司亭换用阿伐曲泊帕的ITP患者获得或维持了临床有意义且持久的血小板应答。

研究设计与样本

  • 回顾性病历审查研究,纳入201例成人原发ITP患者,要求2019年7月1日或之后启动艾曲泊帕或罗米司亭、停药30天内换用阿伐曲泊帕且换药后随访≥6个月。
  • 随访自阿伐曲泊帕启动至末次接触、死亡或研究结束(2025年3月21日)中最早发生者。

主要发现

  • 患者(N=201)最常见停用艾曲泊帕或罗米司亭的原因为疗效不足(59.2%)。
  • 基线血小板<30×10^9/L者(n=79)中,98.7%达到血小板≥30×10^9/L,94.9%达到≥50×10^9/L。
  • ≥30×10^9/L、≥50×10^9/L和≥100×10^9/L应答的中位持久性分别为93.8%、89.6%和67.4%。

关键数值与推荐

  • 应答定义为无挽救治疗情况下至少一次血小板计数≥30×10^9/L、≥50×10^9/L或≥100×10^9/L。
  • 应答持久性定义为应答者中阿伐曲泊帕治疗期间血小板高于应答阈值的时间百分比。

临床怎么用

  • 对艾曲泊帕或罗米司亭疗效不足的ITP患者,换用阿伐曲泊帕可能获得持久血小板应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Real-world data on treatment response after switching between thrombopoietin receptor agonists are limited for patients with immune thrombocytopenia (ITP). The objective of this study is to describe treatment patterns and outcomes in patients with primary ITP who switched from eltrombopag (ELT) or romiplostim (ROMI) to avatrombopag (AVA). We conducted a retrospective chart review study of adults with primary ITP who initiated ELT or ROMI on or after 1 July 2019, switched to AVA within 30 days of ELT/ROMI discontinuation and had ≥6 months follow-up after AVA initiation. Patients were followed from AVA initiation until last contact, death or study end (21 March 2025), whichever occurred earliest. Response was defined as achieving ≥1 platelet count (PC) of ≥30 × 109/L, ≥50 × 109/L or ≥100 × 109/L in the absence of rescue therapy. Response durability was the percentage of time on AVA with PCs above the response threshold among responders. Patients (N = 201) most commonly discontinued ELT/ROMI due to lack of efficacy (59.2%). Among patients with baseline PCs <30 × 109/L (n = 79), 98.7% and 94.9% achieved PCs ≥30 × 109/L and ≥50 × 109/L on AVA respectively. Median response durability was 93.8%, 89.6% and 67.4% for ≥30 × 109/L, ≥50 × 109/L and ≥100 × 109/L respectively. Most patients who switched to AVA from ELT or ROMI achieved or maintained a clinically meaningful and durable platelet response throughout the study period.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Piatek C, Oladapo A, Kolodny S, et al. Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study. Br J Haematol. 2026. PMID: 42136034. doi:10.1111/bjh.70531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。